

पेटेंट कार्यालय
शासकीय जर्नल

**OFFICIAL JOURNAL
OF
THE PATENT OFFICE**

निर्गमन सं. 46/2022
ISSUE NO. 46/2022

शुक्रवार
FRIDAY

दिनांक: 18/11/2022
DATE: 18/11/2022

पेटेंट कार्यालय का एक प्रकाशन
PUBLICATION OF THE PATENT OFFICE

(54) Title of the invention : A long acting injectable in situ gel formulation and a process of preparation thereof

(51) International classification :A61K0009000000, A61K0009060000, A61K0047320000, A61K0047100000, A61L0024000000

(86) International Application No Filing Date :PCT// :01/01/1900

(87) International Publication No : NA

(61) Patent of Addition to Application Number Filing Date :NA :NA

(62) Divisional to Application Number Filing Date :NA :NA

(71)Name of Applicant :
1)JSS Academy of Higher Education and Research
 Address of Applicant :Bannimantap Road, Sri Shivarathreeshwara Nagara, Bannimantap A Layout, Bannimantap, Mysuru – 570 015, Karnataka, India. Mysore -----

Name of Applicant : NA
Address of Applicant : NA

(72)Name of Inventor :
1)Aruna Ganganna
 Address of Applicant :Department of Periodontology, JSS Dental College and Hospital, Bannimantap Road, Sri Shivarathreeshwara Nagara, Bannimantap A Layout, Bannimantap, Mysuru – 570 015, Karnataka, India. Mysore -----

2)Chandrashekar Byalakere Rudraiah
 Address of Applicant :Department of Public Health Dentistry, JSS Dental College and Hospital, Bannimantap Road, Sri Shivarathreeshwara Nagara, Bannimantap A Layout, Bannimantap, Mysuru – 570 015, Karnataka, India. Mysore -----

3)Madhugiri Prakash Venkatesh
 Address of Applicant :Department of Pharmaceutics, JSS College of Pharmacy, Bannimantap Road, Sri Shivarathreeshwara Nagara, Bannimantap A Layout, Bannimantap, Mysuru – 570 015, Karnataka, India. Mysore -----

(57) Abstract :
 The present disclosure provides a solution to the problem of treating and/or management of periodontitis or gingivitis or gum diseases in subjects who are in need thereof. Existing formulations such as topical and gel formulations suffer with various limitations/ challenges in showing intended therapeutic effect. In light of these challenges, the present disclosure provides a formulation that tends to remain in solution form under non-physiological conditions and converts into a gel under physiological conditions due to a stimuli including but not limited to pH, temperature, ions and solvent in the oral cavity. The in situ gel formulation of melatonin as disclosed and claimed is a sustained drug delivery injection formulation to show the intended therapeutic effect in periodontitis.

No. of Pages : 26 No. of Claims : 7